September 30, 2014 10:01 AM ET

Pharmaceuticals

Company Overview of Sanofi-Aventis U.S. LLC

Company Overview

Sanofi-Aventis U.S. LLC, a pharmaceutical company, discovers, develops, produces, and markets therapies in the United States. It offers risedronate sodium tablets, fexofenadine HCI, zolpidem tartrate, zolpidem tartrate extended release, dolasetron mesylate, insuline glulisine, leflunomide, irbesartan-hydrochlorothiazide, irbesartan, benzoyl peroxide gel, fluorouracil cream, and leuprolide acetate for injectable suspension. The company also provides leuprolide acetate for injectable suspension, oxaliplatin injection, sodium hyaluronate, telithromycin tables, sodium sulfacetamide lotion, insulin glargine, enoxaparin sodium injection, triamcinolone acetonide, ciclopirox, clopidogrel bisulfate, ...

55 Corporate Drive

Bridgewater, NJ 08807

United States

Phone:

908-981-5000

Fax:

908-203-7777

Key Executives for Sanofi-Aventis U.S. LLC

Chief Executive Officer of Canada Operations and President of Canada Operations
Chief Executive Officer of Sanofi-Aventis
Age: 54
Chairman of Chattem and Chief Executive Officer of Chattem
Age: 65
President of U S Science and Medical Affairs
Principal Accounting Officer and Vice President of Corporate Accounting
Compensation as of Fiscal Year 2014.

Sanofi-Aventis U.S. LLC Key Developments

ZAI Lab Limited Signs License Agreement with Sanofi-Aventis

ZAI Lab Limited has entered into a global licensing agreement with Sanofi-Aventis U.S. LLC for two novel compounds potential treatment of chronic respiratory diseases including chronic obstructive pulmonary disease (COPD), asthma and idiopathic pulmonary fibrosis (IPF). Under the terms of the agreement, ZAI Lab will be responsible for global development, manufacturing and commercialization of the two clinical ready novel programs. Sanofi will potentially receive development and regulatory approval milestones and tiered royalties from the global net sales of the licensed products.

Sanofi North America Presents at SelectUSA 2013 Investment Summit, Oct-31-2013 02:15 PM

Sanofi North America Presents at SelectUSA 2013 Investment Summit, Oct-31-2013 02:15 PM. Venue: Washington, District Of Columbia, United States. Speakers: Anne Whitaker, CEO.

Covis Pharma to Acquire US Rights from Sanofi-Aventis U.S. LLC for Nilandron(R), Plaquenil(R), Rilutek(R), Uroxatral(R) and Kayexalate(R)

Covis Pharma Sarl announced an agreement with sanofi-aventis U.S. LLC and certain of its affiliates to acquire full commercial rights for Nilandron(R) (nilutamide), Plaquenil(R) (hydroxychloroquine), Rilutek(R) (riluzole), Uroxatral(R) (alfuzosin hydrochloride), and Kayexalate(R) (sodium polystyrene sulfate) in the United States. The aggregate sales for these products in the United States in 2012 were $114.6 million. Sanofi will retain the existing rights for these products in countries outside the United States. Terms of the agreement have not been disclosed.

Similar Private Companies By Industry

Company Name Region
Vaccine Technologies, Inc. United States
Sirion Therapeutics, Inc. United States
Diffusion Pharmaceuticals LLC United States
AREVA Med LLC United States
Angelini Pharma, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Sanofi-Aventis U.S. LLC, please visit www.sanofi-aventis.us. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.